Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil
05 août 2020 08h37 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia
07 juil. 2020 08h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis
16 déc. 2019 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough
09 déc. 2019 06h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
05 sept. 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
12 août 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%
29 juil. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 29, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Idiopathic Pulmonary Fibrosis Treatment Market Worth USD 4.2 billion by 2026
24 juil. 2019 08h46 HE
|
Acumen Research and Consulting
LOS ANGELES, July 24, 2019 (GLOBE NEWSWIRE) -- Acumen Research and Consulting, Recently Published Report On “Idiopathic Pulmonary Fibrosis Treatment Market (By Drug Class: Tyrosine Inhibitors, MAPK...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone
03 juil. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
18 juin 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...